CapVest Acquires Second Nature Brands, the US Based Creator of Premium Snacks and Treats
26.4.2022 15:32:00 EEST | Business Wire | Press release
Funds managed by CapVest Partners LLP (“CapVest”), a leading international private equity investor, have closed the acquisition of Second Nature Brands (“the Company”), a Michigan-based creator of premium, nutritional and better for you snacks and treats, including Kar’s Nuts, Second Nature Snacks, and Sanders Chocolates, from a private equity fund affiliated with Palladium Equity Partners, LLC.
With a heritage stretching over 140 years, the Company is a leader in the fast-growing snacks and treats market, focussing on the nutritional and lifestyle needs of health-conscious consumers. The Company’s brands comprise Kar’s Nuts, the #1 branded trail mix delivering better-for-you, on-the-go fuelling snacks, Second Nature Snacks, a pioneer in natural, non-GMO-verified premium snacks and trail mixes created for a healthy, on-the-go lifestyle, and Sanders Chocolates, the leader in premium, small-batch, kettle-cooked sea salt caramels.
Commenting on the transaction, Othmane Khelladi, Partner, CapVest, said: “Second Nature Brands is a very exciting platform with ambitious plans to grow its presence in the highly attractive snacking and treats market. Through our ownership, we look forward to supporting Vic Mehren and his world-class team in accelerating growth through further investment in product innovation, category leadership and by scaling the existing platform through transformational acquisitions.”
Commenting on behalf of Second Nature Brands, CEO Vic Mehren said: “Our partnership with Palladium has been extraordinarily successful and we thank them for their contributions to Second Nature Brands. With their support, and through the efforts of our great Second Nature Brands team members, Second Nature Brands has transformed into a leader within Snacks and Treats. We’re now thrilled to be partnering with CapVest for our next phase of growth. The CapVest team’s deep consumer food experience will be invaluable as we work to build on our Snacks and Treats platform organically, and inorganically with strategic acquisitions.”CapVest has been investing in food businesses around the world for more over 20 years and has a deep understanding of the consumer food sector. Recent successes include the transformation of Valeo Foods from an Irish-only business with less than €200 million in sales, to a leading global ambient food group with over €1.1 billion in net sales operating in over 106 markets around the world.
CapVest was advised by William Blair (M&A) and Willkie Farr & Gallagher (Legal).
About CapVest
CapVest is a leading international private equity investor that partners with ambitious companies supplying essential goods and services to transform their businesses. As an active and patient investor, CapVest has established a strong record of success in delivering attractive returns by working closely with management in transforming the size and scale of its portfolio companies through a combination of organic and acquisition led growth. For more information, visit www.capvest.co.uk
About Second Nature Brands
Second Nature Brands is a leading creator of snacks and treats that make lives better, naturally. By investing in new product development, thoughtful ingredient sourcing, and innovative business processes, Second Nature Brands is reimagining premium and better-for-you snacks and treats. Under its growing family of brands, Kar’s Nuts®, Second Nature Snacks®, and Sanders Chocolates®, Second Nature Brands has an extensive distribution network across the United States and a growing direct-to-consumer eCommerce presence. Currently, Kar’s Nuts® and Second Nature Snacks® are two of the best-selling trail mix brands in the nation, including the #1 selling Kar’s Sweet ‘n Salty
Mix. Sanders Chocolates is one of the largest kettle-cooked, small-batch crafters of sea salt caramel treats in the U.S. Find out more at Second Nature Brands (www.secondnaturebrandsus.com), Kar’s Nuts (www.karsnuts.com), Second Nature Snacks (www.secondnaturesnacks.com), and Sanders Chocolates (www.sanderscandy.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005746/en/
Contact information
For further information please contact:
Ben Valdimarsson, Reputation Inc
bvaldimarsson@reputation-inc.com
+44 7889805930
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom